Does Revolution Medicines’ pancreatic most cancers drug have even larger potential?

Adam Feuerstein is a senior author and biotech columnist, reporting on the crossroads of drug growth, enterprise, Wall Road, and biotechnology. He’s additionally a co-host of the weekly biotech podcast The Readout Loud and writer of the e-newsletter Adam’s Biotech Scorecard. You’ll be able to attain Adam on Sign at stataf.54.

That is the net model of Adam’s Biotech Scorecard, a subscriber-only e-newsletter. STAT+ subscribers can enroll right here to get it delivered to their inbox.

Revolution Medicines’ daraxonrasib is a sure approval for sufferers with metastatic pancreatic most cancers and tumor development following chemotherapy. The one gating issue appears to be the velocity at which the corporate can submit the drug to the Meals and Drug Administration. As soon as that occurs, daraxonrasib shall be cleared shortly and develop into the brand new customary of care within the second-line setting.

After the drug’s standing ovation throughout the ASCO plenary session, the discuss shifted to how (and when) the usage of daraxonrasib may be expanded to sufferers with newly recognized, metastatic pancreatic most cancers.